AstraZeneca, Sanofi's RSV antibody set for FDA adcomm on Thursday
The FDA’s Antimicrobial Drugs Advisory Committee is set to meet Thursday to discuss AstraZeneca and Sanofi’s RSV antibody nirsevimab, making it the third therapy aimed at respiratory syncytial virus to inch closer to approval this year.
Another committee, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), recently assessed Pfizer’s RSV vaccine and GSK’s RSV vaccine, both of which are for older adults and received FDA approval in May.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.